Juvenescence acquires AI drug discovery company Ro5 to boost R&D capabilities and drive pipeline of medicines to extend healthy lifespan
Ro5 Inc. acquisition enhances artificial intelligence/machine learning drug discovery capabilities Strategic addition strengthens Juvenescence’s AI-enabled therapeutics pipeline and supports partnership with M42 […]
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 […]
Incredible week at Abu Dhabi Global Health Week
Packed with bold ideas, global collaboration, and a shared vision for a future built on preventative, personalised healthcare.
M42 Announces Strategic Investment and Partnership with Leading Biotech Juvenescence
M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.
Relation Therapeutics announces two strategic collaborations with GSK to the tune of $300m
Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company.
Chrysea Unveils Groundbreaking Findings on Spermidine Dietary Intake and Cardiovascular Health at American Physiological Society (APS) Summit.
Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease.
Hevolution Foundation
Our co-founder Dr. Greg Bailey took to the stage in Riyadh at Hevolution Foundation hashtag#GHS2025 with fellow investment leaders.
WHX Dubai
Reflecting on an inspiring & productive week at WHX Dubai - with the latest & best in healthcare innovation.
Buck Institute for Research on Aging
This week, four members of the Juvenescence® team—Kersten Small, Jeff Madwed, Steve Felstead, and myself—had the privilege of visiting the Buck Institute for Research on Aging.
Morphoceuticals
Listen in to Prof Michael Levin & Prof David Kaplan discussing the Morphoceuticals vision and groundbreaking approach of mapping & manipulating the bioelectrome to induce regeneration.